Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-07-29 Director's Dealing
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form dated 29 July 2022, detailing securities dealings in shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, and provides detailed information about derivative contracts and share dealings by CICC Financial Trading Limited. The content focuses on insider or related party transactions involving shares and derivatives, which aligns with reporting of personal share transactions by company directors or connected parties. There is no indication of financial results, management commentary, or regulatory announcements beyond share dealings. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is short and specific to share dealings, confirming this classification with high confidence.
2022-07-29 English
CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORISED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement from CStone Pharmaceuticals regarding changes in the company's joint company secretary, process agent, and authorised representative. It also discusses a waiver from strict compliance with certain Listing Rules. The content focuses on management and governance personnel changes and regulatory compliance waivers related to company secretarial roles. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full report but an announcement about board/management changes and governance compliance. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (7277 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2022-07-28 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is related to insider or director share transactions. The content focuses on the sale of shares by China International Capital Corporation Limited, an exempt principal trader connected with the Offeror. There is no financial report, earnings data, or management discussion. The document is a report of personal share transactions by a party connected to the company, fitting the definition of Director's Dealing filings.
2022-07-27 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is related to insider or director share transactions. The content focuses on the purchase of shares by China International Capital Corporation Limited, an exempt principal trader connected with the Offeror. There is no indication of a full report, financial statements, or regulatory filings beyond this disclosure. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or connected parties.
2022-07-25 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form dated 22 July 2022, detailing securities dealings by CICC Financial Trading Limited related to derivatives and share dealings. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is a regulatory disclosure of share transactions by a connected party. The content focuses on share dealings and derivative contracts, not on financial results, management changes, or meeting materials. It is not a full report, earnings release, or presentation. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives or connected parties.
2022-07-22 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form dated 22 July 2022, reporting dealings in shares of Yankuang Energy Group Company Limited. It details securities transactions by CICC Financial Trading Limited, including purchase and sale of shares, with specifics on number of shares, prices, and nature of dealings. The document references Rule 22 of the Hong Kong Code on Takeovers and Mergers, which relates to disclosure of share dealings by parties connected to takeover offers. This type of document is a notification of insider or related party share transactions, fitting the definition of Director's Dealing filings, which report personal share transactions by company directors and executives or connected parties. The document is not a financial report, earnings release, or announcement of a meeting or vote, but a disclosure of share dealings. Therefore, the correct classification is DIRS (Director's Dealing). The document length is short and focused solely on share dealings, supporting this classification with high confidence.
2022-07-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.